WALTHAM, Mass., March 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX),a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in two upcoming investor
A live webcast of these presentations can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-L1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLLr. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Investor ContactMelissa ForstArgot Partnersmelissa@argotpartners.comTel 212.600.1902
Media ContactDavid Rosen Argot Partners email@example.com Tel 212.600.1902
View original content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-participation-at-two-upcoming-investor-conferences-300607698.html
SOURCE Syndax Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All